Skip to main content
Home
  • en
  • fr
  • Profile
    • About DEINOVE
    • Board of Directors
    • Executive Committee
  • Science
    • Dark biodiversity
    • New antimicrobials
    • Beyond antimicrobials
  • R&D
    • Innovation engine overview
    • Extracting microbial biodiversity
    • Screening for new activity
    • Active compound characterization
    • Preindustrial production
    • Preclinical development
    • Clinical development
  • Technologies
    • Technology platform overview
    • Biodiversity farming
    • Activity testing
    • Advanced analytics
    • Synthetic biology
    • Data Science
    • Fermentation engineering
    • Bioprocess engineering
  • Pipeline
  • Partnering
    • New antimicrobials
    • Beyond antimicrobials
  • Investors
    • Corporate governance
    • DEINOVE Shares
    • Financial Calendar
    • Documentation Center
    • Press releases
    • Investor relations
  • News
    • Press releases
    • Events
  1. Home
  2. News
  3. Press releases

Press releases

29.03.2018

2017: ambitions confirmed, milestones reached, and financial results in line with the development strategy

Acceleration of the Antibiotics program: €14.6m of funding by Bpifrance (including € 10.4m for the DEINOVE Group) and structuring of the...
22.03.2018

DEINOVE expands its innovative antibiotic portfolio by signing a license option agreement with REDX PHARMA

The program developed by REDX PHARMA focuses on a new class of antibiotics aimed at treating the most lethal infections (caused by...
08.03.2018

DEINOVE collaborates with NAICONS to discover new antibiotics in the frame of the AGIR project

DEINOVE expands the AGIR project’s field of investigation for the discovery of novel antibiotic structures by accessing the strain bank of...
26.02.2018

DEINOVE announces the success of its cosmetic active ingredient’s production process industrialization

World premiere in Deinococcus fermentation successfully performed at the several cubic meters scale; The first batch of carotenoid...
19.02.2018

DEINOVE announces its financial calendar for 2018

DEINOVE (Euronext Growth Paris: ALDEI), a biotech company that discovers, develops, and produces high-value compounds from rare bacteria,...
30.01.2018

DEINOVE and Hallstar’s Oléos, partners in the development of a new cosmetic active ingredient

Development of an innovative cosmetic active ingredient combining the exclusive properties of Deinove’s strains and Oléos' patented Oleo-...
18.12.2017

DEINOVE launches the industrial production of its first carotenoid

Deinove’s production process gaining momentum: fermentation scale-up is planned at the BIOGIS Center, SAS PIVERT's technological platform...
20.11.2017

DEINOVE and GREENTECH are making progress in the co-development of their cosmetic active ingredient

Six pre-selected strains are in the testing phase to validate the final choice of the active ingredient to be marketed in 2018. Technology...
23.10.2017

DEINOVE confirms the launch of its first cosmetic active ingredient during the first half of 2018 and targets the very dynamic segment of anti-aging skincare

This active ingredient with proven antioxidant and healing properties is an innovative carotenoid produced by Deinococcus bacteria. The...
28.09.2017

2017 half-year consolidated results: stability of net loss major progress on R&D programs in health, nutrition and cosmetics

Cash position: +€6.6m at June 30, 2017 compared to +€9.3m at December 31, 2016. Half-year net loss of DEINOVE Group (composed of DEINOVE...
  • « first
  • ‹ previous
  • …
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • …
  • next ›
  • last »

News

  • Press releases
  • Events
  • Careers
  • Contact
  • Legal Info
  • Site map
  • Privacy Policy

Follow us

         

Stay in touch

Subscribe to our newsletter

Contact us

Location

ZAC Euromédecine II, Cap Sigma, 1682 Rue de la Valsière, 34790 Grabels, France

+33 (0)4 48 19 01 00

Home